GlassScriptPhysician profile
Mandy Lee Fluitt
NPI 1386042927
$4,271.48
in general payments reported to CMS, 2019-2025
36 companies · $36.61 in 2025
The $36.61 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,658 · 2022: $1,218 · 2023: $679 · 2024: $679 · 2025: $36.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,394.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $734.16 | 2021-2025 | |
| Novo Nordisk INC | $534.30 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $448.56 | 2021-2024 | Airsupra, Farxiga, Fasenra |
| Lilly USA, LLC | $347.74 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Abbott Laboratories | $236.35 | 2021-2023 | Freestyle Libre |
| Insmed, INC. | $205.57 | 2023-2024 | Arikayce |
| Pfizer INC. | $187.10 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $160.50 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.30 | 2021-2024 | Trulance, Xifaxan |
| Amgen INC. | $117.29 | 2021-2024 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $113.34 | 2021 | |
| Amarin Pharma, INC. | $110.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.30 | 2021-2024 | Ofev |
| Janssen Pharmaceuticals, INC | $89.70 | 2021-2022 | |
| Viiv Healthcare Company | $86.05 | 2024-2025 | Dovato |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $77.08 | 2021-2023 | Veozah |
| Dexcom, INC. | $72.48 | 2021-2022 | |
| Glaxosmithkline, LLC. | $69.11 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $63.53 | 2022 | |
| Currax Pharmaceuticals LLC | $56.60 | 2021-2022 | |
| Exact Sciences Corporation | $43.37 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $28.52 | 2022-2023 | |
| Esperion Therapeutics, INC. | $28.40 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.47 | 2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $21.42 | 2024 | Voquezna |
| Horizon Therapeutics Plc | $17.96 | 2022 | |
| Dynavax Technologies Corporation | $17.42 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.28 | 2021 | |
| Sumitomo Pharma America, INC. | $17.04 | 2024 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $16.04 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.02 | 2023 | Gvoke Hypopen |
| Ibsa Pharma INC. | $15.28 | 2021 | |
| Merck Sharp & Dohme LLC | $13.45 | 2021 | |
| Biogen, INC. | $13.16 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.26 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Fluitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.